SLC6A15 Membrane Protein Introduction

Introduction of SLC6A15

SLC6A15 is encoded by SLC6A15 gene. It belongs to the solute carrier family 6 which has been extensively studied during the past few decades because it offers numerous possibilities for therapeutic applications. SLC6A15 is widely expressed in the mammalian brain and mediates the release of neurotransmitters from extracellular space to neurons and glial cells. It plays an important role in regulating neurotransmitter signals and homeostasis. Studies conducted on SLC6A15 show that it is a target for a wide range of mental illness treatment, such as severe depression, anxiety, and mental illness.

Basic Information of SLC6A15
Protein Name Sodium-dependent neutral amino acid transporter B(0)AT2
Gene Name SLC6A15
Aliases B0AT2, NTT73, SBAT1
Organism Homo sapiens (Human)
UniProt ID Q9H2J7
Transmembrane Times 12
Length (aa) 730

Function of SLC6A15 Membrane Protein

SLC6A15, also named as solute carrier family 6 (neurotransmitter transporter), member 15, is a Na+/Cl- dependent neurotransmitter transporter. It is mainly expressed in brain, placenta, and esophagus. Recent studies have indicated that SLC6A15 variants are associated with major depressive disorder (MDD). It plays an important role in modulating anxiety and depressive-like behavior. In addition, SLC6A15 has been studied as a potential drug target in various psychiatric diseases, including major depression, anxiety disorders, attention deficit hyperactivity disorder, and epilepsy.

 SLC6A15 Membrane Protein Introduction Fig.1 Phylogenetic tree of the SLC6 transporter family. (Kristensen, 2011)

Application of SLC6A15 Membrane Protein in Literature

  1. Szopa A., et al. Withdrawal of caffeine after its chronic administration modifies the antidepressant-like activity of atypical antidepressants in mice. Changes in cortical expression of Comt, Slc6a15 and Adora1 genes. Psychopharmacology (Berl). 2018, 235(8): 2423–2434. PubMed ID: 29882086

    This article analyzes the expression level of SLC6A15 in mice cerebral cortex (Cx) after treatment with a series of doses of caffeine. These results indicate that caffeine on day 15 decreases the expression of SLC6A15, and Comt, Slc6a15 and Adora1 genes can modify the activity of antidepressants.

  2. Wang L., et al. A combined study of SLC6A15 gene polymorphism and the resting-state functional magnetic resonance imaging in first-episode drug-naive major depressive disorder. Genet Test Mol Biomarkers. 2017, 21(9): 523-530. PubMed ID: 28915082

    This article reports that the relationship between SLC6A15 gene polymorphism and major depressive disorder (MDD). These results indicate that SLC6A15 rs1545843 could be involved in the pathogenesis of MDD.

  3. Chandra R., et al. Reduced Slc6a15 in nucleus accumbens D2-neurons underlies stress susceptibility. J Neurosci. 2017, 37(27):6527-6538. PubMed ID: 28576941

    Authors in this group examine the expression of SLC6A15 in the ventral striatum. The data suggest SLC6A15 plays an important role in depression treatment and stress susceptibility.

  4. Choi S., et al. Effects of a polymorphism of the neuronal amino acid transporter SLC6A15 gene on structural integrity of white matter tracts in major depressive disorder. PLoS One. 2016, 11(10):e0164301. PubMed ID: 27723767

    Authors in this group examine a gene polymorphism of SLC6A15 (rs1545853) in patients who suffer from major depressive disorder. The results show that rs1545853 is strongly related with the white matter integrity of the parahippocampal cingulum in MDD patients.

  5. Santarelli S., et al. SLC6A15, a novel stress vulnerability candidate, modulates anxiety and depressive-like behavior: involvement of the glutamatergic system. Stress. 2016, 19(1):83-90. PubMed ID: 26585320

    This article aims to reveal the role of mouse slc6a15 in modulating brain function and behavior, especially in relation to stress as a key risk factor for the development of mood disorders. The data suggest slc6a15 plays a role in modulating anxiety and depressive-like behavior, and it is possibly mediated by its impact on glutamatergic neurotransmission.

SLC6A15 Preparation Options

To obtain the soluble and functional target protein, the versatile Magic™ membrane protein production platform in Creative Biolabs enables many flexible options, from which you can always find a better match for your particular project. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SLC6A15 antibody development services.

As a forward-looking research institute as well as a leading custom service provider in the field of membrane protein, Creative Biolabs has won good reputation among our worldwide customers for successfully accomplishing numerous challenging projects including generation of many functional membrane proteins. Please feel free to contact us for more information.


  1. Kristensen A S, et al. (2011). SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev. 63(3), 585-640.

Online Inquiry

Verification code
Click image to refresh the verification code.


USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
Europe: Heidenkampsweg 58, 20097 Hamburg, Germany
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us